You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
Kura Oncology reports early activity for darlifarnib–cabozantinib combination in cabozantinib‑pretreated ccRCC
Login
Username:

Password:


Related Headlines

GSK strengthens pulmonary hypertension pipeline with USD950m acquisition of 35Pharma

Poolbeg Pharma secures MHRA approval for POLB 001 trial as US research highlights multi-billion dollar potential

Asgard Therapeutics appoints chief medical officer

Mestag Therapeutics to present targeted LTBR agonist MST-0312 at AACR Annual Meeting

CrossBridge Bio to be acquired by Eli Lilly

Groupe Rocher partners with Dassault Systèmes to accelerate cosmetics innovation using virtual twin technology

hVIVO signs influenza human challenge trial agreement with Traws Pharma

IDEAYA Biosciences and Servier report positive results from Phase 2/3 trial of darovasertib/crizotinib combination

Hoth Therapeutics reports positive HT-VA CRADA data

Kelun-Biotech reports Phase II study results for sac-TMT at 2026 SGO

Genmab reports positive safety data for Rina-S combination in ovarian cancer

GSK reports strong early-stage data for B7-H4 ADC in gynaecological cancers

FDA grants priority review to ifinatamab deruxtecan in small cell lung cancer

Almirall expands supercomputing and AI collaboration with Barcelona Supercomputing Center

Qlucore launches AI-based AML test

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026